Mental health diagnosis and medication changes after initiation of elexacaftor/tezacaftor/ivacaftor
The rate of MH medication use increased significantly from baseline at all time points in PwCF not previously prescribed MH medications, while rate of MH medication use remained consistent for those already on medications pre-ETI.
Authors
- Hua Shen (ORCID: https://orcid.org/0000-0002-5180-8670)
- Yi Shi (ORCID: https://orcid.org/0000-0002-3068-2044)
- Stephanie Duehlmeyer (ORCID: https://orcid.org/0000-0002-0861-0124)
- Casey Tak (ORCID: https://orcid.org/0000-0002-1203-1782)
- Rebecca S. Pettit (ORCID: https://orcid.org/0000-0002-6049-0481)
- Charissa W. Kam (ORCID: https://orcid.org/0000-0003-3419-2613)
- Brittany A. Wright (ORCID: https://orcid.org/0000-0001-6620-1727)
- Morgan C. Jones
- Emma M. Tillman (ORCID: https://orcid.org/0000-0001-8019-9811)
- Cameron J. McKinzie (ORCID: https://orcid.org/0000-0003-1401-5628)
- S. Foushee
Institutions
- University of North Carolina at Chapel Hill (US)
- Children's Mercy Hospital (US)
- University of North Carolina Health Care (US)
- University of Utah (US)
- Riley Hospital for Children (US)
- University of North Carolina Hospitals (US)
- University of Iowa Health Care (US)
- University of Louisville Hospital (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- University of California, Davis (US)
Publication Details
- Journal
- Annals of the American Thoracic Society
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1513/annalsats.202505-552oc
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00